Fabio Lievano

FABIO LIEVANO‚ MD‚ is the Senior Director‚ Clinical Risk Management and Safety Surveillance‚ at Merck & Co.‚ Inc. Dr. Lievano is a physician and epidemiologist with experience on a variety of clinical‚ epidemiological‚ drug safety‚ pharmacovigilance‚ risk management‚ risk minimization and public health programs during the last 15 years. Dr. Lievano worked as medical epidemiologist supervising public health program in Europe at the World Health Organization (WHO) European Regional Office (EURO) for 3 years. He received epidemiology training at the U.S. Centers for Disease Control and Prevention (CDC)‚ in the prestigious Epidemiology Intelligence Service and then as Senior Epidemiologist implemented a variety of research and analytical studies for 6 years at the CDC. Dr. Lievano pharmaceutical experience during the last 6 years includes; viral and bacterial vaccines‚ antibiotics‚ antimicotics‚ Hepatitis B and C drugs‚ HIV drugs‚ oral hypoglucemiants‚ incretin enhancers‚ insulin (injected and inhaled)‚ G.I.‚ and CNS drugs. Dr. Lievano has authored over 40 articles‚ in addition to numerous abstracts‚ and poster presentations in major scientific journals and international and national conferences. Dr. Lievano is an expert in pharmacovigilance and clinical risk assessment.

SELECTED PUBLICATIONS

• An Alternative to Disproportionality: A frequency-based method for pharmacovigilance data mining. Jokinen J, Lievano F, et al. Therapeutic Innovation & Regulatory Science 1-6 September 8, 2017.
• The future of safety science is happening now: The modernization of the benefit-risk paradigm. Lievano F, et al. Pharmacoepidemiology and Drug Safety 2017 Aug 26(8):869-74.
• An Overview of the Post-licensure Safety Data for GARDASIL/SILGARD® 2006-2014. Vichnin M, Lievano F, et al. Pediatric Infectious Diseases 2015 Sep;34(9):893-91.
• Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013). Lievano F et al. ID Week 2014, Philadelphia October 2014.
• Postmarketing Experience with Serious Skin Reactions after Boceprevir during the First 3 Years after Licensure. Lievano F et al. ID Week 2014, Philadelphia October 2014.
• No Adverse Safety Signals Observed After Exposure to Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine During Pregnancy: Six-Year Pregnancy Registry Data®. Goss MA, Lievano F, Seminack M, Buchanan K., Dana A. Presented at the American College of Obstetrics and Gynecology Annual Meeting Chicago April, 2014.
• Lievano F, Galea SA, Thornton M, Wiedmann RT, Manoff S, Tran T, Amin MA, Seminack MM, Vagie KA, Dana A, and Plotkin SA. Measles, Mumps, and Rubella Virus Vaccine. A Review of 32 Years of Clinical and Postmarketing Experience. Vaccine Nov 2012;30(48):6918-26.
• Goss MA, Lievano F, Seminack M, Buchanan K, Dana A. No Adverse Signals Observed after Exposure to Human Papillomavirus Type 6/11/16/18 Vaccine during Pregnancy: Five- Year Pregnancy Registry Data. A dual presentation for the 52nd Annual Meeting of the Teratology Society, Baltimore MD June 23, 2012 and EUROGIN, Prague 2012, July 8-11, 2012.
• de Moraes JC, Toscano CM, de Barros EN, Kemp B, Lievano F, Jacobson S, Afonso AM, Strebel PM, Cairns KL, and the VigiFex Group. Etiologies of Rash and Illnesses in Campinas, Brazil. Journal of Infectious Diseases 2011;204:S627-36.
• Hedy Teppler, Deborah D. Brown, Randi Y. Leavitt, Peter Sklar, Hong Wan, Xia Xu, Fabio Lievano, Heidi P. Lehman, T. Christopher Mast, Bach-Yen T. Nguyen. Long-Term Safety from the Raltegravir Clinical Development Program. Current HIV Research 2011;9:40-53.
• Lievano F, et al. Reported Adverse Experiences in Patients With Unknown Immunosuppressive Conditions Vaccinated with Varivax, 47th Annual IDSA, Philadelphia PA, October 2009.
• Lievano F et al. A 13-Year Review of Postmarketing Rashes Within 42 Days Postvaccination in Patients Who Received Varicella Virus Vaccine Live (Oka/Merck) 48th Annual ICAAC/IDSA, Washington DC, October 2008.
• Vijayaraghavan M, Lievano F, Cairns L, Wolfson L, Nandy R, Ansari A, Golaz A, Mashal T,
• Salama P. Economic evaluation of measles catch-up and follow-up campaigns in Afghanistan in 2002 and 2003. Disasters 2006;30(2):256-269.
• Araki D, Bruno J, Salama P, Sadeed A, Sadozai N, Nandy R, Cairns L, Lievano F. Adverse events following immunization attributable to measles vaccine are rare. Disasters 2006;30(2):270-272.
• Huerta C, Montoro M, Sanchez B, Rivero E, Lievano F, Garcia-Rodriguez L. Risk factors for intestinal ischemia in the general population. Abstract for the 2006 International Conference of Pharmacoepidemiology and Therapeutic Risk Management.
• Seeger J, Lievano F, Rivero E, Earnest D, Shetzline M, Walker A, Holden W. Nested casecontrol
• study validate results of the Zelnorm Epidemiological Study (ZEST). Abstract for the 2006 International Conference of Pharmacoepidemiology and Therapeutic Risk Management.
• Seeger J, Lievano F, Rivero E, Earnest D, Shetzline M, Walker A, Holden W. No increased risk of abdominal or pelvic surgery associated to tegaserod exposure: the Zelnorm Epidemiological Study (ZEST). Abstract for the 2006 International Conference of Pharmacoepidemiology and Therapeutic Risk Management.
• Coppola D, Lievano F, Hertzog J. Glimepiride and glibenclamide: Summary of Toxic Epidermal Necrolysis and Stevens Johnson Syndrome. Abstracts of the 2004 ISoP Annual Conference. Drug Safety 2004. Vol 27(12):925.
• Lievano F. CDC. Progress toward measles elimination - Region of the Americas, 2002-2003. JAMA June 2, 2004 Vol 291 (21): 2535-2537.
• Lievano F, Papania M, Helfand R, Rota P, Harpaz R, Bellini W. Lack of evidence of measles virus shedding in people with inapparent measles infections. Journal of Infectious Diseases (JID) Measles Elimination in United States. May 1, 2004. Vol 189; Suppl 1:S165-70.